A 41-year-old pregnant woman with multiple virological failures started darunavir, enfuvirtide, zidovudine and lamivudine at week 28 of pregnancy. During week 38, the patient had a viral load <400 copies/mL and a CD4 count of 180 cells/mm3 (13%). The child was found to be in good health, with negative HIV-polymerase chain reactions at birth, at two and at six months.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - December 1, 2007. See [http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf] (last checked 15 January 2008).
2.
Brennan-BensonP, PakianathanM, RiceP. Enfurvirtide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta.AIDS2006; 20: 297–9.
3.
CohanD, FeakinsC, WaraD. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen.AIDS2005; 19: 989–90.
4.
MeyohasMC, LacombeK, CarbonneB, Morand-JoubertL, GirardPM. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough.AIDS2004; 18: 1966–8.
5.
WensingAM, BoucherCA, van KasterenM, van DijkenPJ, GeelenSP, JuttmannJR. Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir.AIDS2006; 20: 1465–7.
6.
ClotetB, BellosN, MolinaJM. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.Lancet2007; 369: 1169–78.
7.
MadrugaJV, BergerD, McMurchieM. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.Lancet2007; 370: 49–58.
8.
FentonC, PerryCM. Darunavir: in the treatment of HIV-1 infection.Drugs2007; 67: 2791–801.
9.
MolinaJM, HillA. Darunavir (TMC114): a new HIV-1 protease inhibitor.Exp Opin Pharmacother2007; 8: 1951–64.
